Giuliano Vivanet
Systemic therapy for the treatment of endometrial cancer
Neri M.;Melis G. B.;PIRAS, BEATRICE;Vallerino V.;Paoletti A. M.;Madeddu C.;Scartozzi M.;Mais V.
2019-01-01
Abstract
Introduction: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer. Areas covered: Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies. Expert opinion: Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies.File | Dimensione | Formato | |
---|---|---|---|
2019-EOP_Neri et al.pdf Solo gestori archivio
Descrizione: articolo principale
Tipologia: versione editoriale
Dimensione 2.19 MB
Formato Adobe PDF
|
2.19 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.